Niemann-Pick Disease Type A

This is the most severe form of Niemann-Pick Disease. It usually appears in infancy. It causes fats to build up in the liver, spleen, and brain. This leads to liver damage, enlarged liver and spleen, and severe brain problems, often resulting in early death.

Condition

What people with Niemann-Pick Disease Type A report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Niemann-Pick Disease Type A

What It Is

Niemann-Pick disease type A is a rare inherited disease in which the body cannot break down a fatty substance called sphingomyelin. The substance builds up inside cells of the liver, spleen, lungs and brain, and those cells gradually stop working and die. Type A is the most severe form of a broader condition called acid sphingomyelinase deficiency (ASMD), and specialists now often call it infantile neurovisceral ASMD because it affects both the nervous system and the internal organs from infancy. Babies with type A usually develop a noticeably enlarged liver and spleen by about 3 months of age and have trouble feeding and gaining weight. Development may seem on track for several months, then stalls somewhere between 6 and 15 months and begins to go backward, with loss of movement and other skills a baby had gained. Lung damage also builds up, making chest infections common and serious. The name Niemann-Pick covers more than one disease. Type B (chronic visceral ASMD) comes from the same enzyme problem but progresses slowly, does not damage the brain and is often compatible with life into adulthood. Type C is a separate disease caused by different genes, with a different course and different treatment.

Causes & Risk Factors

Type A is caused by changes (variants) in the SMPD1 gene, which carries the instructions for an enzyme called acid sphingomyelinase. This enzyme works inside lysosomes, the compartments that break down and recycle material within cells. In type A there is little or no working enzyme, which is why sphingomyelin accumulates so quickly and the disease is so severe. Milder forms of ASMD occur when some enzyme activity remains. The disease is inherited in an autosomal recessive pattern. A child is affected only after inheriting a non-working copy of the gene from each parent. The parents are usually healthy carriers who had no reason to suspect anything, and nothing either of them did during pregnancy caused it. When both parents are carriers, each pregnancy has a 1 in 4 chance of an affected child. Type A is more common among people of Ashkenazi Jewish descent, where it affects roughly 1 in 40,000 people compared with about 1 in 250,000 for types A and B combined in the general population. Three gene variants account for more than 90% of type A cases in that community, which makes carrier testing especially informative there.

How It's Diagnosed

Doctors usually first suspect type A when an infant has a large liver and spleen, poor weight gain and, a little later, a pause or loss in development. An eye examination often finds a cherry-red spot, a characteristic finding at the back of the eye that is seen in all children with type A. The diagnosis is confirmed with a blood test that measures how much acid sphingomyelinase activity is present, usually in white blood cells or a dried blood spot. Very low or absent activity establishes the disease. Laboratories often test for Gaucher disease at the same time, because it can look similar. Genetic testing of the SMPD1 gene follows. Finding the two specific variants confirms the type, helps predict how severe the course will be, and makes carrier testing for relatives and testing in a future pregnancy possible. Several other conditions also cause an enlarged liver and spleen in infancy, including Niemann-Pick type C and lysosomal acid lipase deficiency, so specialist evaluation by a metabolic or genetics team matters. Raised blood fats and foamy cells in tissue samples can point toward ASMD but do not replace the enzyme test.

Treatment Options

There is currently no treatment that stops or reverses the brain damage in type A. Care focuses on keeping the child as comfortable as possible and supporting the family. Specialists recommend involving a palliative care team early. Palliative care is not limited to the end of life: it helps families plan care around the child's comfort and the family's priorities. Practical support can include help with nutrition and feeding as swallowing and weight gain become harder, physical therapy, treatment for muscle stiffness (spasticity), and prompt treatment of infections. Olipudase alfa (Xenpozyme) is an enzyme replacement therapy, a laboratory-made version of the missing enzyme given by intravenous infusion every 2 weeks. It is approved in the United States for the effects of ASMD outside the brain and nervous system. Its studies were in people with the slower forms (type B and the intermediate type A/B), where it reduced liver and spleen size and improved lung function, platelet counts and children's growth. It does not treat the neurological decline that defines type A, and there are no published results in children with type A. Infusions can cause allergic reactions, occasionally severe, so they are given with medical monitoring. Whether it has any role for an individual child is a decision to make with a metabolic specialist.

What to Expect

Type A progresses steadily. Over months, children lose motor and communication skills, feeding becomes more difficult and lung involvement leaves them vulnerable to infections. Most children with type A die before age 3, often from respiratory failure following a chest infection. This is a hard prognosis to hear, and the course still differs somewhat from child to child. Day to day, much of the work is about comfort: feeding support, physical therapy, easing muscle stiffness, and planning how infections will be handled and where the child will be cared for. Palliative and home-care teams, social workers and family counseling can help parents carry this, make decisions in advance rather than in a crisis, and care for siblings. Genetic counseling is part of follow-up. Once both SMPD1 variants are known, other relatives can be tested to learn whether they are carriers, and parents can consider testing in a future pregnancy.

When to Seek Help

Arrange an evaluation if an infant has a swollen belly or an enlarged liver or spleen, is not gaining weight, or stops making developmental progress or loses skills. Genetic counseling is worth seeking before or during a pregnancy if a relative has had Niemann-Pick disease or if you are of Ashkenazi Jewish descent and have not had carrier screening. For a child already diagnosed, contact the care team promptly about fever, cough, or faster or harder breathing, since chest infections are the most common serious complication. Also call about new feeding problems such as coughing or choking with feeds, or signs of discomfort the current plan is not relieving. It helps to agree with the care team in advance what to do if breathing becomes severely labored, because families make different choices about hospital treatment.

Questions to Ask Your Doctor

  1. 1.Which type of acid sphingomyelinase deficiency does our child have, and what do the gene results tell us about how the disease is likely to progress?
  2. 2.What can palliative care and home support offer us now, and how do we reach them when problems come up?
  3. 3.Is olipudase alfa (Xenpozyme) worth considering for our child, and what could it realistically change?
  4. 4.How should we plan for chest infections and breathing problems, including where we would want our child to be treated?
  5. 5.Which relatives should be offered carrier testing, and what options do we have for a future pregnancy?

Last reviewed • Oct 2026

Educational content, not medical advice.